Sana Biotechnology, Inc.
NASDAQ:SANABiotechnology
Healthcare
$1.74 +1.23%
+$0.04 today
- Market cap
- $521.36M
- Beta
- 2.16
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.87
52W Low $2.58High $6.55
Volume 4.00M
Average 3.76M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$190.96M
FY 2025 · Annual
Net Income
-$244.17M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 12.75M |
| Gross Profit | 0 | 0 | 0 | 0 | (12.75M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 306.5M | 201M | 219.84M | 208.68M | 131.98M |
| Selling, General & Admin | 50.41M | 71.56M | 73.3M | 64.04M | 44.3M |
| Operating Expenses | 356.91M | 272.56M | 293.14M | 272.72M | 178.21M |
| Depreciation & Amortization | 11.07M | 15.63M | 24.56M | 17.39M | 12.75M |
| EBITDA | (344.86M) | (253.85M) | (258.7M) | (249.37M) | (231.42M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (356.91M) | (272.56M) | (293.14M) | (272.72M) | (190.96M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 676K | 3.76M | 9.94M | 10.47M | 3.85M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 981K | 3.09M | 9.89M | 5.96M | (53.21M) |
| Income Before Tax | (355.93M) | (269.48M) | (283.26M) | (266.76M) | (244.17M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (355.93M) | (269.48M) | (283.26M) | (266.76M) | (244.17M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.14) | (1.43) | (1.46) | (1.16) | (0.96) |
| EPS (Diluted) | (2.14) | (1.43) | (1.46) | (1.16) | (0.96) |
| 166.43M | 188.34M | 194.54M | 230.89M | 253.23M | |
| 166.43M | 188.34M | 194.54M | 230.89M | 253.23M |
SANA Earnings Waterfall · TTM
NASDAQ:SANA · Revenue to Net Income
Key Ratios
EPS$-0.92
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-4.0
P/S Ratio0.0
Analysis
$0 of revenue converted into -$242.0M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.92, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 6, 2026 | |
| 8-K | Current report | Sep 8, 2026 |
How much revenue does SANA generate?
Sana Biotechnology, Inc. (SANA) reported $0.00 of revenue in fiscal 2025.
Is SANA profitable?
Sana Biotechnology, Inc. (SANA) reported -$244.17M of net income.
Continue the stock analysis
Jump to another research area for this company.